Compare Amylx Pharmaceuticals Inc (AMLX) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Vanguard Information Technology Index Fund ETF trades at $116.67. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Information Technology Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | VGT | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | — |
52-Week High | $18.70 | $125.77 |
52-Week Low | $7.64 | $83.59 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
VGT trades at $118.08, up 0.31% with a bullish technical signal from moving averages. The ETF shows strong institutional backing and positive media coverage highlighting its tech sector exposure and low 0.09% expense ratio. Recent news emphasizes VGT's outperformance versus QQQ and its role in AI-driven tech investments.
Outlook remains positive given tech sector momentum and AI growth catalysts, though risks include sector volatility and valuation concerns. Analyst sentiment favors VGT for broad tech diversification with competitive fees supporting long-term growth potential amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
